EIKN (NASDAQ:EIKN) Now Covered by Analysts at Wedbush

Wedbush assumed coverage on shares of EIKN (NASDAQ:EIKN) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The brokerage issued an underperform rating and a $7.00 target price on the stock.

Separately, Wall Street Zen raised shares of EIKN to a “hold” rating in a research note on Monday, February 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell” and an average target price of $7.00.

EIKN Stock Performance

NASDAQ EIKN opened at $13.64 on Thursday. EIKN has a 1-year low of $13.28 and a 1-year high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.